[1] |
LIU Wendong, CUI Huanhuan, WANG Xiaohan, SU Xian, WANG Haixue.
Status and thinking of Parmacovigilance regulatory system during clinical trials of the pediatric drug in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1002-1006.
|
[2] |
JIANG Jiandong.
Development and clinical safety of paediatric medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 1-6.
|
[3] |
LIANG Jiaqi, SHAO Rong, LIU Pengcheng, LI Ming, RENG Jingtian, TANG Ren, WANG Yue.
Characteristics of dear health care provider letters in Europe and America
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 275-278.
|
[4] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[5] |
ZHANG Dan, LYU Jintao, SONG Haibo, ZHANG Bing, JIN Yongnan, SA Rina, ZHANG Xiaomeng, LIN Zhijian.
Drug Risk Communication among Drug Regulatory Agencies in the European Union, the United States and Asia
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 845-849.
|
[6] |
JU Shan, LIU Yinghui, WANG Yawen, TENG Yingying, JIANG Yan, DENG Gang, SUN Lei.
Clinical Evaluation of Medical Devices Seen from International Coordination Documents
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(11): 1062-1065.
|
[7] |
WEI Fuqian, ZHANG Wei, YANG Yue.
Drug Risk Communication between Drug Regulatory Agencies and the Public
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(10): 949-952.
|
[8] |
WU Shifu, JIN Yi, CHANG Hong, TIAN Yuejie, XU Kui, XU Lili, GUO Fanling, ZHANG Jingdong.
Drug Risk Communication in the European Union and United States between Regulators and the Public
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(2): 87-92.
|
[9] |
TIAN Yi, YANG Yue, TIAN Li-juan.
Progress and Implication of FDA Risk Communication in the United States
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(1): 24-27.
|
[10] |
Wang Ling, Huang Ling.
Construction of the Data Sharing Platform of Adverse Drug Reaction Reporting and Thinking on Risk Communication
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(9): 536-541.
|
[11] |
SUN Hua ,YU Ling-Hong ,WEI Huai-Ling ,ZHANG Dan .
Effects of Bicyclol on the Inhibition of Gap Junctional Intercellular Communication by DDT in WB-F344 Cells
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(7): 385-389.
|
[12] |
LU Chang-fei, TIAN Chun-hua ,TIAN Yue-jie, LIU Cui-li ,XIE Yan-jun .
Exploration on Adverse Drug Reaction Signal Detection, Validation and Statistics Analysis Methods: Based on the Clindamycin Injection's Renal Toxicity Adverse Reaction Monitoring Data.
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(4): 222-227.
|
[13] |
XU Li-fen.
Unreasonable Phenomena Excation about Medicine Use Found in the Process of Advisory Service
[J]. Chinese Journal of Pharmacovigilance, 2011, 8(4): 233-234.
|
[14] |
CHEN Chong-ze .
The Role of the Information Communication in Drug Risk Management
[J]. Chinese Journal of Pharmacovigilance, 2010, 7(10): 611-612.
|